nach oben

Erschienen in:

11.01.2024 | Original Article

The combination of doxazosin and metyrosine as a preoperative treatment for pheochromocytomas and paragangliomas

verfasst von: Yuka Ohmachi, Masaaki Yamamoto, Yuiko Inaba, Shohei Makino, Shin Urai, Risa Matsumoto, Hironori Bando, Keitaro Kanie, Yasutaka Tsujimoto, Yuma Motomura, Yuriko Sasaki, Yuka Oi-Yo, Naoki Yamamoto, Masaki Suzuki, Michiko Takahashi, Genzo Iguchi, Maki Kanzawa, Junya Furukawa, Katsumi Shigemura, Satoshi Mizobuchi, Wataru Ogawa, Hidenori Fukuoka

Erschienen in: Endocrine | Ausgabe 2/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Preoperative medical management is critical to prevent intraoperative cardiovascular complications in patients with pheochromocytomas and paragangliomas (PPGLs). Initial treatment involves α-adrenergic receptor blockers. However, while the routine use of metyrosine alongside these blockers is not strongly recommended due to a lack of evidence supporting its efficacy and associated safety concerns, there are previous studies on combination therapy with phenoxybenzamine and metyrosine. There are few reports on combination therapy with the selective α1-adrenergic receptor blocker doxazosin. Therefore, we investigated this combination treatment, which theoretically can affect perioperative outcomes in patients with PPGLs. To our knowledge, this is the first such study.

Methods

This retrospective single-center observational study involved 51 patients who underwent surgical resection of PPGLs at Kobe University Hospital between 2014 and 2022. All patients received doxazosin at maximum doses. Fourteen patients received concomitant metyrosine, while 37 received doxazosin alone. Their perioperative outcomes were compared.

Results

No severe event, such as acute coronary syndrome, was observed in either group. Intraoperatively, the doxazosin + metyrosine group exhibited a lower median minimum systolic blood pressure (56 [54–60] vs. 68 [59–74] mmHg, P = 0.03) and required lower median remifentanil (P = 0.04) and diltiazem (P = 0.02) doses than the doxazosin-alone group.

Conclusion

The combination of metyrosine and doxazosin as a preoperative treatment for PPGLs affects intraoperative circulatory hemodynamics, such as a reduced occurrence of blood pressure elevation during surgery. Further research is necessary to identify patients who will benefit most from this combination treatment.

J.W. Lenders, G. Eisenhofer, M. Mannelli, K. Pacak, Phaeochromocytoma. Lancet 366, 665–675 (2005). https://doi.org/10.1016/S0140-6736(05)67139-5CrossRefPubMed

C.M. Beard, S.G. Sheps, L.T. Kurland, J.A. Carney, J.T. Lie, Occurrence of pheochromocytoma in Rochester, Minnesota, 1950 through 1979. Mayo Clin. Proc. 58, 802–804 (1983)PubMed

N. Kimura, R. Takayanagi, N. Takizawa et al. Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma. Endocr. Relat. Cancer 21, 405–414 (2014). https://doi.org/10.1530/ERC-13-0494CrossRef

M.M. Walther, H.R. Keiser, W.M. Linehan, Pheochromocytoma: evaluation, diagnosis, and treatment. World J. Urol. 17, 35–39 (1999). https://doi.org/10.1007/s003450050102CrossRefPubMed

J.W. Lenders, Q.Y. Duh, G. Eisenhofer et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 99, 1915–1942 (2014). https://doi.org/10.1210/jc.2014-1498CrossRefPubMed

J.H. Kim, H.C. Lee, S.J. Kim et al. Perioperative hemodynamic instability in pheochromocytoma and sympathetic paraganglioma patients. Sci. Rep. 11, 18574 (2021). https://doi.org/10.1038/s41598-021-97964-3CrossRefPubMedPubMedCentral

J. Naranjo, S. Dodd, Y.N. Martin, Perioperative management of pheochromocytoma. J. Cardiothorac. Vasc. Anesth. 31, 1427–1439 (2017). https://doi.org/10.1053/j.jvca.2017.02.023CrossRef

H. Wachtel, I. Cerullo, E.K. Bartlett et al. Preoperative metyrosine improves cardiovascular outcomes for patients undergoing surgery for pheochromocytoma and paraganglioma. Pancreas 44, 360 (2015)

M.A. Kinney, B.J. Narr, M.A. Warner, Perioperative management of pheochromocytoma. J. Cardiothorac. Vasc. Anesth. 16, 359–369 (2002). https://doi.org/10.1053/jcan.2002.124150CrossRefPubMed

10.

W.F. Kvale, G.M. Roth, W.M. Manger, J.T. Priestley, Pheochromocytoma. Circulation 14, 622–630 (1956). https://doi.org/10.1161/01.CIR.14.4.622CrossRefPubMed

11.

G. Lebuffe, D. Dosseh, G. Tek et al. The effect of calcium channel blockers on outcome following the surgical treatment of phaeochromocytomas and paragangliomas. Anesthesia 60, 439–444 (2005). https://doi.org/10.1111/j.1365-2044.2005.04156.xCrossRef

12.

K. Zawadzka, K. Więckowski, P. Małczak et al. Selective vs non-selective alpha-blockade prior to adrenalectomy for pheochromocytoma: systematic review and meta-analysis. Eur. J. Endocrinol. 184, 751–760 (2021). https://doi.org/10.1530/EJE-20-1301CrossRefPubMed

13.

S. Yoon, S.L. Gianturco, L.L. Pavlech, K.D. Storm, M.V. Yuen, A.N. Mattingly, Phenoxybenzamine hydrochloride: Summary report. University of Maryland Center of Excellence in Regulatory Science and Innovation (M-CERSI). https://archive.hshsl.umaryland.edu/handle/10713/15464 (2020). Accessed 12 Dec 2023

14.

C. Prys-Roberts, J.R. Farndon, Efficacy and safety of doxazosin for perioperative management of patients with pheochromocytoma. World J. Surg. 26, 1037–1042 (2002). https://doi.org/10.1007/s00268-002-6667-zCrossRefPubMed

15.

Y. Shao, R. Chen, Z.J. Shen et al. Preoperative alpha blockade for normotensive pheochromocytoma: is it necessary? J. Hypertens. 29, 2429–2432 (2011). https://doi.org/10.1097/HJH.0b013e32834d24d9CrossRefPubMed

16.

M. Araujo-Castro, R. Garcia Centeno, M.C. López-García et al. Risk factors for intraoperative complications in pheochromocytomas. Endocr. Relat. Cancer 28, 695–703 (2021). https://doi.org/10.1530/ERC-21-0230CrossRefPubMed

17.

H.K. Van Den, A. Paspala, N. Chander et al. To block, or not to block … is it still the question? Effectiveness of alpha- and beta-blockade in phaeochromocytoma surgery: an institutional analysis. Ann. R. Coll. Surg. Engl. 104, 138–143 (2022). https://doi.org/10.1308/rcsann.2021.0133CrossRef

18.

L.M. Gruber, S. Jasim, A. Ducharme-Smith, T. Weingarten, W.F. Young Jr., I. Bancos, The role for metyrosine in the treatment of patients with pheochromocytoma and paraganglioma. J. Clin. Endocrinol. Metab. 106, e2393–e2401 (2021). https://doi.org/10.1210/clinem/dgab130CrossRefPubMedPubMedCentral

19.

R.R. Perry, H.R. Keiser, J.A. Norton et al. Surgical management of pheochromocytoma with the use of metyrosine. Ann. Surg. 212, 621–628 (1990). https://doi.org/10.1097/00000658-199011000-00010CrossRefPubMedPubMedCentral

20.

J. Steinsapir, A.A. Carr, L.M. Prisant, E.D. Bransome Jr., Metyrosine and pheochromocytoma. Arch. Intern. Med. 157, 901–906 (1997). https://doi.org/10.1001/archinte.1997.00440290087009CrossRefPubMed

21.

The Japan Endocrine Society, Clinical practice guideline of pheochromocytoma paraganglioma] (in Japanese). Jpn. J. Endocrinol. 94, 1–90 (2018). https://doi.org/10.1507/endocrine.94.S.August_1CrossRef

22.

K. Tanaka, I. Hara, K. Yamaguchi, M. Takeda, A. Takenaka, M. Fujisawa, Laparoscopic resection of a lower posterior mediastinal tumor: feasibility of using a transdiaphragmatic approach. Urology 70, 1215–1218 (2007). https://doi.org/10.1016/j.urology.2007.09.042CrossRefPubMed

23.

A. Sjoerdsma, K. Engelman, S. Spector, S. Udenfriend, Inhibition of catecholamine synthesis in man with alpha-methyl-tyrosine, an inhibitor of tyrosine hydroxylase. Lancet 2, 1092–1094 (1965). https://doi.org/10.1016/S0140-6736(65)90062-0CrossRefPubMed

24.

M. Naruse, F. Satoh, A. Tanabe et al. Efficacy and safety of metyrosine in pheochromocytoma/paraganglioma: a multi-center trial in Japan. Endocr. J. 65, 359–371 (2018). https://doi.org/10.1507/endocrj.EJ17-0276CrossRefPubMed

25.

T.N. Weingarten, T.L. Welch, T.L. Moore et al. Preoperative levels of catecholamines and metanephrines and intraoperative hemodynamics of patients undergoing pheochromocytoma and paraganglioma resection. Urology 100, 131–138 (2017). https://doi.org/10.1016/j.urology.2016.10.012CrossRefPubMed

26.

H. Wachtel, E.H. Kennedy, S. Zaheer et al. Preoperative metyrosine improves cardiovascular outcomes for patients undergoing surgery for pheochromocytoma and paraganglioma. Ann. Surg. Oncol. 22, S646–S654 (2015). https://doi.org/10.1245/s10434-015-4862-zCrossRefPubMed

27.

J.J. Butz, T.N. Weingarten, A.N. Cavalcante et al. Perioperative hemodynamics and outcomes of patients on metyrosine undergoing resection of pheochromocytoma or paraganglioma. Int. J. Surg. 46, 1–6 (2017). https://doi.org/10.1016/j.ijsu.2017.08.026CrossRefPubMed

28.

H. Arima, Y. Tanizaki, Y. Kiyohara et al. Validity of the JNC VI recommendations for the management of hypertension in a general population of Japanese elderly: the Hisayama study. Arch. Intern. Med. 163, 361–366 (2003). https://doi.org/10.1001/archinte.163.3.361CrossRefPubMed

29.

N. Sheffy, I. Bentov, B. Mills, B.G. Nair, G.A. Rooke, M.S. Vavilala, Perioperative hypotension and discharge outcomes in non-critically injured trauma patients, a single centre retrospective cohort study. Injury 48, 1956–1963 (2017). https://doi.org/10.1016/j.injury.2017.06.023CrossRefPubMed

30.

M.L. Ogletree, J. Sprung, C.S. Moravec, Effects of remifentanil on the contractility of failing human heart muscle. J. Cardiothorac. Vasc. Anesth. 19, 763–767 (2005). https://doi.org/10.1053/j.jvca.2004.11.034CrossRefPubMed

31.

R.N. Brogden, R.C. Heel, T.M. Speight, G.S. Avery, α-Methyl-p-tyrosine: a review of its pharmacology and clinical use. Drugs 21, 81–89 (1981). https://doi.org/10.2165/00003495-198121020-00001CrossRefPubMed

Titel: The combination of doxazosin and metyrosine as a preoperative treatment for pheochromocytomas and paragangliomas
verfasst von: Yuka Ohmachi
Masaaki Yamamoto
Yuiko Inaba
Shohei Makino
Shin Urai
Risa Matsumoto
Hironori Bando
Keitaro Kanie
Yasutaka Tsujimoto
Yuma Motomura
Yuriko Sasaki
Yuka Oi-Yo
Naoki Yamamoto
Masaki Suzuki
Michiko Takahashi
Genzo Iguchi
Maki Kanzawa
Junya Furukawa
Katsumi Shigemura
Satoshi Mizobuchi
Wataru Ogawa
Hidenori Fukuoka
Publikationsdatum: 11.01.2024
Verlag: Springer US
Erschienen in: Endocrine / Ausgabe 2/2024
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-023-03681-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

The combination of doxazosin and metyrosine as a preoperative treatment for pheochromocytomas and paragangliomas